Celltrion Wants Janssen To Give Up Docs From Samsung Suit

Law360, New York (December 5, 2017, 10:04 PM EST) -- Celltrion Inc. on Tuesday asked a Massachusetts federal court to order Janssen Biotech Inc. to turn over documents from Janssen’s recently dismissed lawsuit against Samsung Bioepis Co. Ltd., arguing that the information is relevant for its defense against Janssen’s instant suit over Pfizer Inc.’s biosimilar anti-inflammatory biologic Remicade.

Janssen, a Johnson & Johnson subsidiary, doesn’t contest the relevance of the requested documents, transcripts and filings as they relate to a substance used to grow cells and the patent at issue in the instant suit, Celltrion said....
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.